NanoBiotechnology

, Volume 4, Issue 1–4, pp 1–8 | Cite as

Evaluation of Immunotargeted Gold Nanoshells as Rapid Diagnostic Imaging Agents for HER2-Overexpressing Breast Cancer Cells: A Time-based Analysis

  • Lissett R. Bickford
  • Joseph Chang
  • Kun Fu
  • Jiantang Sun
  • Ying Hu
  • André Gobin
  • Tse-Kuan Yu
  • Rebekah A. Drezek
Article

Abstract

Biomedical nanotechnology offers superior potential for diagnostic imaging of malignancy at the microscopic level. In addition to current research focused on dual-imaging and therapeutic applications in vivo, these novel particles may also prove useful for obtaining immediate diagnostic results in vitro at the patient bedside. However, translating the use of nanoparticles for cancer detection to point-of-care applications requires that conditions be optimized such that minimal time is needed for diagnostic results to become available. Thus far, no reports have been published on minimizing the time needed to achieve acceptable optical contrast of cancer cells incubated with nanoparticles. In this study, we demonstrate the use of gold nanoshells targeted to anti-HER2 antibodies that produce sufficient optical contrast with HER2-overexpressing SK-BR-3 breast cancer cells in only 5 min. This work validates the proof of concept that nanoshells targeted to extracellular biomarkers can be used to enhance cancer diagnostic imaging for use in point-of-care applications.

Keywords

nanoshells point-of-care diagnostics optical imaging cancer diagnosis 

Notes

Acknowledgments

We thank Vengadesan Nammalvar and Adrien Wang for expert technical assistance on nanoshell fabrication. We also thank Nastassja Lewinski for SEM imaging and Christine Wogan for editing assistance. This work was supported by a Department of Defense Congressionally Directed Breast Cancer Research Program Era of Hope Scholar Award to Rebekah Drezek and Tse-Kuan Yu, the Center for Biological and Environmental Nanotechnology (EEC-0118007 and EEC-0647452), the Beckman Foundation, and the John and Ann Doerr Fund for Computational Biomedicine.

References

  1. 1.
    Loo C, Lowery A, Halas N, West J, Drezek R. Nano Lett 2005;5(4):709–11.PubMedCrossRefADSGoogle Scholar
  2. 2.
    Loo C, Hirsch L, Lee M-H, Chang E, West J, Halas N, Drezek R. Optics Lett 2005;30:1012–4.CrossRefADSGoogle Scholar
  3. 3.
    Lowery A, Gobin A, et al. Int J Nanomed 2006;1:149–54.CrossRefGoogle Scholar
  4. 4.
    Gobin AM, Lee MH, Halas NJ, James WD, Drezek RA, West JL. Nano Lett 2007;7:1929–34.PubMedCrossRefADSGoogle Scholar
  5. 5.
    Sokolov K, Follen M, Aaron J, Pavlova I, Malpica A, Lotan R, et al. Cancer Res 2003;63:1999–2004.PubMedGoogle Scholar
  6. 6.
    El-Sayed IH, Huang X, El-Sayed MA. Nano Lett 2005;5(5):829–34.PubMedCrossRefADSGoogle Scholar
  7. 7.
    Sun J, Zhu MQ, Fu K, Lewinski N, Drezek R. Int J Nanomed 2007;2(2):235–40.Google Scholar
  8. 8.
    Gao X, Cui Y, Levenson RM, Chung LW, Nie S. Nat Biotechnol 2004;22(8):969–76.PubMedCrossRefGoogle Scholar
  9. 9.
    Cao L, et al. J Am Chem Soc 2007;129:11318–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Huang X, El-Sayed IH, Qian W, El-Sayed MA. J Am Chem Soc 2006;128:2115–20.PubMedCrossRefGoogle Scholar
  11. 11.
    Durr NJ, Larson T, Smith DK, Korgel BA, Sokolov K, Ben-Yakar A. Nano Lett 2007;7:941–5.PubMedCrossRefADSGoogle Scholar
  12. 12.
    Yu C, Nakshatri H, Irudayaraj J. Nano Lett 2007;7(8):2300–6.PubMedCrossRefADSGoogle Scholar
  13. 13.
    Sukhanova A, Devy J, Venteo L, Kaplan H, et al. Anal Biochem 2004;324:60–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Zajac A, Song D, Qian W, Zhukov T. Colloids Surf B Biointerfaces 2007;58:309–14.PubMedCrossRefGoogle Scholar
  15. 15.
    Weigum SE, Floriano PN, Christodoulides N, McDevitt JT. Lab Chip 2007;7(8):995–1003.PubMedCrossRefGoogle Scholar
  16. 16.
    Culha M, Stokes DL, Griffin GD, Vo-Dinh T. JBO 2004;9(3):439–43.ADSGoogle Scholar
  17. 17.
    National Comprehensive Cancer Network. Breast cancer treatment guidelines for patients. Version IX. 2007.Google Scholar
  18. 18.
    Mojica CM, Bastani R, Boscardin WJ, Ponce NA. Cancer Control 2007;14(2):176–82.PubMedGoogle Scholar
  19. 19.
    Guthrie TH. Breast J 1995;1(6):376–9.CrossRefGoogle Scholar
  20. 20.
    Klimberg VS, Harms S, Korourian S. Surg Oncol 1999;8:77–84.PubMedCrossRefGoogle Scholar
  21. 21.
    Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, Jeong JH, Wolmark N. NEJM 2002;347:1233–41.PubMedCrossRefGoogle Scholar
  22. 22.
    Hirsch LR, Halas NJ, West JL. Methods Mol Biol 2005;303:101–11.PubMedGoogle Scholar
  23. 23.
    Stöber W, Fink A, et al. J Colloid Interface Sci 1968;26:62–9.CrossRefGoogle Scholar
  24. 24.
    Duff DG, Baiker A, Edwards PP. Langmuir 1993;9:2301–9.CrossRefGoogle Scholar
  25. 25.
    Hayes DF, Walker TM, et al. Int J Oncol 2002;21(5):1111–7.PubMedGoogle Scholar
  26. 26.
    Kornilova ES, Taverna D, et al. Oncogene 1992;7(3):511–9.PubMedGoogle Scholar

Copyright information

© Humana Press Inc. 2008

Authors and Affiliations

  • Lissett R. Bickford
    • 1
  • Joseph Chang
    • 1
  • Kun Fu
    • 1
    • 2
  • Jiantang Sun
    • 1
  • Ying Hu
    • 1
  • André Gobin
    • 3
  • Tse-Kuan Yu
    • 2
  • Rebekah A. Drezek
    • 1
    • 4
  1. 1.Department of BioengineeringRice UniversityHoustonUSA
  2. 2.Department of Radiation OncologyThe University of Texas M.D. Anderson Cancer CenterHoustonUSA
  3. 3.Department of BioengineeringUniversity of LouisvilleLouisvilleUSA
  4. 4.Department of Electrical and Computer EngineeringRice UniversityHoustonUSA

Personalised recommendations